Epiomic Epidemiology Series: Prader-Willi Syndrome Forecast In 21 Major Markets 2018-2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Epiomic Epidemiology Series: Prader-Willi Syndrome Forecast In 21 Major Markets 2018-2028” report has been added to ResearchAndMarkets.com’s offering.
Prader-Willi syndrome (PWS) is a genetic disease caused by the loss of function of several genes in a particular region of chromosome 15, affecting many parts of the body. These genes provide instructions for making molecules called small nucleolar RNAs (snRNAs) which have a variety of functions. PWS initially comprises weak muscle tone (hypotonia), feeding difficulties, poor growth and delayed development, usually persisting for 12 months after birth. Around the age of 2 years, this is followed by weight gain and obesity due to hyperphagia, hypogonadism and global developmental delay.
This report provides the current prevalent population for PWS across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Denmark, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the publisher’s analysis team, PWS patients grouped by various features, symptoms and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for PWS include:Cardiovascular problems Obstructive sleep apnoea and respiratory disorders Type 2 diabetes mellitus Autism spectrum disorder behavioural characteristics Seizures Hip dysplasia Scoliosis
Reasons to buyAbility to quantify patient populations in global PWS market to target the development of future products, pricing strategies and launch plans. Further insight into the prevalence of the subdivided types of PWS and identification of patient segments with high potential. Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries. Better understanding on the impact of specific co-morbid conditions on the prevalent population of PWS patients. Identification of PWS patient sub-populations that require treatment. Better understanding of the specific markets that have the largest number of PWS patient. For more information about this report visit https://www.researchandmarkets.com/research/gjl6j6/epiomic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005673/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Drugs by Therapeutic Area
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 01:37 PM/DISC: 09/19/2018 01:37 PM